The innovation drug going global and CXO sector has never truly cooled down this year. Names like $WUXI XDC(02268.HK), $PHARMARON(03759.HK), $ANTENGENE-B(06996.HK), and $EVEREST MED(01952.HK) have all popped up together again. The potential for pipeline and orders is still there, and the sector's spark could flare up again at any moment.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments